Clinical Trial Update: 1st Line Durvalumab in PS 2 NSCLC Patients [Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 2 study of first-line durvalumab in performance status 2 non-small cell lung cancer patients (stages IV and IIIB). The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: NSCLC Stage IV, NSCLC Stage IIIB | Phase 2 | Status: ACTIVE_NOT_RECRUITING